CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
企業コードCVRX
会社名CVRx Inc
上場日Jun 30, 2021
最高経営責任者「CEO」Mr. Kevin Hykes
従業員数206
証券種類Ordinary Share
決算期末Jun 30
本社所在地9201 West Broadway Avenue
都市MINNEAPOLIS
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号55445
電話番号17634162850
ウェブサイトhttps://www.cvrx.com/
企業コードCVRX
上場日Jun 30, 2021
最高経営責任者「CEO」Mr. Kevin Hykes
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし